首页> 外文OA文献 >Personalised medicine for multiple sclerosis care.
【2h】

Personalised medicine for multiple sclerosis care.

机译:用于多发性硬化症护理的个性化药物。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Treatments with a range of efficacy and risk of adverse events have become available for the management of multiple sclerosis (MS). However, now the heterogeneity of clinical expression and responses to treatment pose major challenges to improving patient care. Selecting and managing the drug best balancing benefit and risk demands a new focus on the individual patient. Personalised medicine for MS is based on improving the precision of diagnosis for each patient in order to capture prognosis and provide an evidence-based framework for predicting treatment response and personalising patient monitoring. It involves development of predictive models involving the integration of clinical and biological data with an understanding of the impact of disease on the lives of individual patients. Here, we provide a brief, selective review of challenges to personalisation of the management of MS and suggest an agenda for stakeholder engagement and research to address them.
机译:具有多种功效和不良事件风险的治疗方法已可用于治疗多发性硬化症(MS)。但是,现在临床表达和治疗反应的异质性对改善患者护理提出了重大挑战。选择和管理最能平衡利益和风险的药物,需要重新关注每个患者。 MS的个性化药物基于提高每个患者的诊断准确性,以便捕获预后并提供基于证据的框架来预测治疗反应和个性化患者监测。它涉及预测模型的开发,该模型涉及临床和生物学数据的整合,并了解疾病对个别患者生命的影响。在此,我们简要,选择性地回顾了MS管理个性化所面临的挑战,并提出了利益相关方参与和研究的议程,以解决这些挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号